Their characteristic dependency on angiogenesis led to several phase 2 trials of bevacizumab (Avastin®), a humanized antibody targeted against vascular endothelial growth factor (VEGF) in patients with recurrent GBM (Jain et al, 2007). This evidence concerns the gene VEGFA and glioblastoma.